Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review

Obesities, Journal Year: 2025, Volume and Issue: 5(2), P. 26 - 26

Published: April 18, 2025

Obesity represents a global health challenge, with critical and urgent need for long-term, sustainable management strategies. Tirzepatide is novel dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist. At first approved the treatment of type 2 diabetes mellitus, tirzepatide one latest clinically commercially available pharmacological options obesity management. This narrative review aimed to synthesize existing clinical evidence on efficacy safety in non-diabetic obese individuals. A comprehensive literature search was conducted using PubMed, Scopus, Web Science, ClinicalTrials.gov, Google Scholar databases identify relevant trials, meta-analyses, original studies assessing weight-loss impact from 2022 onwards. Synthesized indicated that achieved up 20.9% weight loss over 72 weeks (SURMOUNT-1), 18.4% after lifestyle intervention (SURMOUNT-3), 17.5% Chinese adults (SURMOUNT-CN), 25.3% continued 88 (SURMOUNT-4). Meta-analyses confirmed higher odds ≥5–20% versus semaglutide liraglutide, significantly reducing body mass index, waist circumference, blood pressure, atherosclerotic cardiovascular disease risk. Health-related quality life improved greater loss, gastrointestinal side effects (nausea, diarrhea, constipation) were common but mild moderate, <5% discontinuation. significant cardiometabolic benefits, individuals, further research needed long-term efficacy, safety, application.

Language: Английский

---

Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review

Diseases, Journal Year: 2025, Volume and Issue: 13(5), P. 129 - 129

Published: April 22, 2025

Obesity is a growing global health challenge, necessitating effective treatment options beyond lifestyle interventions. This narrative review explores established and emerging pharmacotherapies for weight management, including parenteral agents like Liraglutide, Semaglutide, Setmelanotide, Tirzepatide, as well peroral medications such Phentermine, Phentermine/Topiramate, Bupropion/Naltrexone, Orlistat, Metformin. Newer treatments Cagrilintide Bimagrumab show promise enhancing loss outcomes. Parenteral GLP-1 receptor agonists demonstrate superior efficacy compared to traditional medications, with gastrointestinal side effects being the most common. Artificial intelligence presents intriguing opportunities enhance strategies; however, its integration into clinical practice remains investigational requires rigorous validation. While current anti-obesity deliver significant benefits, future research must determine efficacy, safety, cost-effectiveness of AI-driven approaches. includes exploring how AI can complement combination therapies tailor personalized interventions, thereby grounding potential benefits in robust evidence. Future directions will focus on integrating trials refine personalize obesity management strategies.

Language: Английский

---

Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface

BMC Global and Public Health, Journal Year: 2024, Volume and Issue: 2(1)

Published: Sept. 17, 2024

Off-label use of semaglutide for non-diabetic weight loss (which regulators have linked to social media promotion) created worldwide supply shortages. We evaluated interest measured by online search behavior gauge and conventional print reporting's effect on interest.

Language: Английский

---

Association between MCU Gene Polymorphisms with Obesity: Findings from the All of Us Research Program

Genes, Journal Year: 2024, Volume and Issue: 15(4), P. 512 - 512

Published: April 19, 2024

Obesity is a public health crisis, and its prevalence disproportionately affects African Americans in the United States. Dysregulation of organelle calcium homeostasis associated with obesity. The mitochondrial uniporter (MCU) complex primarily responsible for homeostasis. multifactorial disease which genetic underpinnings such as single-nucleotide polymorphisms (SNPs) may contribute to progression. objective this study was identify variations MCU anthropometric measurements obesity All Us Research Program. We used an additive model assess association between traits (body mass index (BMI), waist hip circumference) selected SNPs 19,325 participants (3221 normal weight 16,104 obese). Eleven common minor allele frequency ≥ 5% were analysis. observed three self-reported Black/African American (B/AA) men, six B/AA women increased risk obesity, whereas White nine protective against development. This found associations providing evidence potential predictor susceptibility adults.

Language: Английский

---

An integrated investigation combining network pharmacology and computer simulation dissects the potential mechanism of anti-obesity of Monascus pigments (MPs)

Food Bioscience, Journal Year: 2024, Volume and Issue: 60, P. 104459 - 104459

Published: May 30, 2024

Language: Английский

---

Controlled Quercetin Release by Fluorescent Mesoporous Nanocarriers for Effective Anti-Adipogenesis

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 5441 - 5458

Published: June 1, 2024

Introduction: Quercetin (QUER), a flavonoid abundant in fruits and vegetables, is emerging as promising alternative therapeutic agent for obesity treatment due to its antioxidant anti-adipogenic properties. However, the clinical application of QUER limited by poor solubility, low bioavailability, potential toxicity at high doses. To address these challenges, this study aims develop an advanced drug delivery system using fluorescent mesoporous silica nanoparticles (FMSNs) coated with polydopamine (PDA) efficient sustained inhibit adipogenesis. Methods: The research included synthesis PDA-coated FMSNs encapsulation QUER, characterization their structures, systematic investigation release behavior QUER. DPPH assay was used evaluate radical scavenging potential. Concentration-dependent effects on 3T3-L1 cell proliferation, cellular uptake adipogenesis inhibition were investigated. Results: exhibited well-aligned structures. confirmed potential, FMSNs-QUER@PDA showing 53.92 ± 3.48% 72 h, which higher than FMSNs-QUER (44.66 0.57%) free (43.37 5.04%). cells highlighted enhanced efficacy uptake, 1.5-fold increase compared uncoated FMSNs. Adipogenesis also improved, relative lipid accumulation 44.6 4.6%, 37.3 36.5 7.3% 2.5, 5, 10 μM concentrations, respectively. Conclusion: successfully developed tailored system, emphasizing effects. FMSNs, especially when PDA, exhibit properties delivery, providing comprehensive approach that integrates technology efficacy. Keywords: nanoparticles, quercetin, coating, inhibition,

Language: Английский

---

Medicinal Plant Extracts Against Cardiometabolic Risk Factors Associated with Obesity: Molecular Mechanisms and Therapeutic Targets

Published: July 2, 2024

Obesity has increasingly become a worldwide epidemic, as demonstrated by epidemiological and clinical studies. may lead to development of broad spectrum cardiovascular diseases (CVDs), such coronary heart disease (CHD), hypertension, failure (HF), cerebrovascular disease, atrial fibrillation (AF), ventricular arrhythmias, sudden cardiac death (SCD). In addition there are other cardiometabolic risk factors (CRFs) visceral adiposity, dyslipidemia, insulin resistance, diabetes, elevated levels fibrinogen, C-reactive protein others, all which increase the CVD events. Mechanisms involved between obesity mainly include oxidative stress, inflammation, adipokines dysregulation, cause maladaptive structural functional alterations heart, particularly left (LV) remodeling diastolic dysfunction. Natural products plants, provide diversity nutrients different bioactive compounds, including phenolics, flavonoids, terpenoids, carotenoids, anthocyanins, vitamins, minerals, fibers, possess wide range biological activities antihypertensive, antilipidemic, antidiabetic, activities, thus conferring benefits. this review, we discussed main therapeutic interventions using extracts from herbs plants in preclinical trials with protective properties targeting CRFs. Molecular mechanisms targets for prevention treatment CRFs also reviewed.

Language: Английский

---

Drugs used in the treatment of obesity

Farmacist ro, Journal Year: 2023, Volume and Issue: 5(214), P. 12 - 12

Published: Jan. 1, 2023

The obesity epidemic is one of society’s most urgent public health concerns. Significant scientific efforts and researches are directed to the elucidation its complex physiopathology, as well clinical management weight-related comorbidities. treatment highly focused on patient, so various pharmacological surgical approaches may be required, depending affected persons. An effective in involves lifestyle interventions, complementary medicine, alternative therapy, including drug or bariatric surgery. Currently, FDA has approved four appetite inhibitors (phentermine, phendimetrazine, diethylpropion, benzphetamine) recommended for short-term use (≤12 weeks), five drugs (orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide) long-term use, two preparations (metreleptin, setmelanotide) people with rare syndromes, determined by three specific genetic conditions. For obesity, recommends six major (phentermine/topiramate, semaglutide, orlistat, setmelatonin), while European Agency Medicine only substances.

Language: Английский

---

Potential therapies for obesity management: Exploring novel frontiers

Current Problems in Cardiology, Journal Year: 2024, Volume and Issue: 49(3), P. 102382 - 102382

Published: Jan. 4, 2024

Language: Английский

---

Sweetening the deal: An infodemiological study of worldwide interest in semaglutide using Google Trends

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: April 23, 2024

Abstract Background: Off-label use of semaglutide for non-diabetic weight loss (presumably driven by social media) created world-wide supply shortages. We evaluated interest measured online search behavior to gauge media and conventional print reporting’s effect on interest. Methods: Using Google Trends Extended Health multiple sampling, we retrieved regional (ROI) all countries extracted timelines top queries with median ROI≥20 January 2021–August 2023 using the “semaglutide” topic. obtained reporting from ProQuest database. estimated within-country between-country Granger causality analysis. determined changepoints trends within each country joinpoint regression. prominent themes in Natural Language Processing thematic Results: Some showed increases analysis that coverage could only partially explain interest, some preceded others. Joinpoint identified up four significant changepoints. One episode Dr Oz show (TV event) drove strong peaks numerous countries. Specific agreement between country-specific themes. Weight was a major theme most Conclusions: GTEH data provided insights into global variation. Studies focusing specific which include can elucidate drivers underlying explosion off-label semaglutide.

Language: Английский

---